Shinichi Nunoda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shinichi Nunoda has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Atsushi Suzuki
Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan
1 shared publicationFumiyo Kato
Department of Pediatrics, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
1 shared publicationKaoru Ikeno
Department of Pediatrics, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
1 shared publicationKenji Fukushima
Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan
1 shared publicationKenta Uto
Department of Pathology, Tokyo Women's Medical University, Tokyo, Japan
1 shared publicationMikiko Ishido
Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan
1 shared publication
Latest Publications
- 1 August 2021
- Published by Elsevier in Journal of Cardiology Cases
- Vol. 24 (2) , 60-63
Complete remission from post-heart transplant lymphoproliferative disorder: A case report
- 1 August 2021
- Published by Elsevier in Journal of Cardiology Cases
- Vol. 24 (2) , 60-63
Complete remission from post-heart transplant lymphoproliferative disorder: A case report
- Open Access
- 1 June 2019
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 24 (3) , 220-226
Impact of pretransplant antibodies on outcomes after heart transplantation
Purpose of review: Since the discovery of human leukocyte antigen (HLA) in the 1950s, there has been great interest in the role of antibodies in posttransplant rejection. The development of the lymphocyte toxicity test by Terasaki et al. in the 1960s was the first step toward understanding the role of antibodies in posttransplant rejection. Recent findings: Subsequently, various organs have been transplanted and improving posttransplant outcomes have become a focus of research. In particular, methods to measure antibodies that affect posttransplant outcomes, including anti-HLA antibodies, and methods to desensitize patients from specific antibodies have been explored. One recent method for measuring antibodies is called the solid-phase assay, which uses purified HLA fixed to microbeads. This assay does not use donor lymphocytes and allows clinicians to test the reactivity of patient serum against a panel of antibodies. It has also enabled the identification of specific anti-HLA antibodies using a single HLA. Summary: In addition to advances in methods to measure and analyze anti-HLA antibodies, the clinical impact of non-HLA antibodies has also received much attention recently.
- 1 June 2019
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 24 (3) , 220-226
Open AccessImpact of pretransplant antibodies on outcomes after heart transplantation
Purpose of review: Since the discovery of human leukocyte antigen (HLA) in the 1950s, there has been great interest in the role of antibodies in posttransplant rejection. The development of the lymphocyte toxicity test by Terasaki et al. in the 1960s was the first step toward understanding the role of antibodies in posttransplant rejection. Recent findings: Subsequently, various organs have been transplanted and improving posttransplant outcomes have become a focus of research. In particular, methods to measure antibodies that affect posttransplant outcomes, including anti-HLA antibodies, and methods to desensitize patients from specific antibodies have been explored. One recent method for measuring antibodies is called the solid-phase assay, which uses purified HLA fixed to microbeads. This assay does not use donor lymphocytes and allows clinicians to test the reactivity of patient serum against a panel of antibodies. It has also enabled the identification of specific anti-HLA antibodies using a single HLA. Summary: In addition to advances in methods to measure and analyze anti-HLA antibodies, the clinical impact of non-HLA antibodies has also received much attention recently.
- 25 February 2019
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 83 (3) , 681-683
Survival of Heart Transplant Candidates in Japan
Background: In Japan, there are more patients waiting for heart transplants (HTXs) than available organs. Methods and Results: Since July 2010, 68 pediatric and 366 adult patients aged <60 years applied for HTX candidacy with the Japanese Circulation Society's HTX Committee. No significant differences in freedom from death or HTX were observed between pediatric Status 1 and Status 2 patients. More adult Status 1 patients reached the endpoint of death or HTX than adult Status 2 patients. Pediatric patients (Status 1 and 2) did not have better survival than adult Status 1 or Status 2 patients. Conclusions: Pediatric patients should be prioritized over adult patients for HTX.
- 25 February 2019
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 83 (3) , 681-683
Survival of Heart Transplant Candidates in Japan
Background: In Japan, there are more patients waiting for heart transplants (HTXs) than available organs. Methods and Results: Since July 2010, 68 pediatric and 366 adult patients aged <60 years applied for HTX candidacy with the Japanese Circulation Society's HTX Committee. No significant differences in freedom from death or HTX were observed between pediatric Status 1 and Status 2 patients. More adult Status 1 patients reached the endpoint of death or HTX than adult Status 2 patients. Pediatric patients (Status 1 and 2) did not have better survival than adult Status 1 or Status 2 patients. Conclusions: Pediatric patients should be prioritized over adult patients for HTX.
- 1 April 2016
- Published by Elsevier in Journal of Cardiology Cases
- Vol. 13 (4) , 125-128
Combination therapy with corticosteroid and mycophenolate mofetil in a case of refractory cardiac sarcoidosis
- 1 April 2016
- Published by Elsevier in Journal of Cardiology Cases
- Vol. 13 (4) , 125-128
Combination therapy with corticosteroid and mycophenolate mofetil in a case of refractory cardiac sarcoidosis